{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:04:10Z","timestamp":1769047450077,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-04149-7","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T09:38:29Z","timestamp":1765964309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of sequential chemoradiotherapy versus concurrent chemoradiotherapy on prognosis in adjuvant treatment after radical hysterectomy for cervical cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Yuhong","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"4149_CR1","first-page":"e197","volume":"11","author":"D Singh","year":"2023","unstructured":"Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO global cervical cancer elimination initiative, the lancet. Glob Health. 2023;11:e197-206.","journal-title":"Glob Health"},{"key":"4149_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13091292","author":"T Bianchi","year":"2023","unstructured":"Bianchi T, Grassi T, Bazzurini L, Di Martino G, Negri S, Fruscio R, et al. Radical hysterectomy in early-stage cervical cancer: abandoning the one-fits-all concept. J Pers Med. 2023. https:\/\/doi.org\/10.3390\/jpm13091292.","journal-title":"J Pers Med"},{"key":"4149_CR3","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2023.13939","volume":"26","author":"Y Awazu","year":"2023","unstructured":"Awazu Y, Fukuda T, Noda T, Uchikura E, Nanno S, Imai K, et al. CLPTM1L expression predicts recurrence of patients with intermediate\u2011 and high\u2011risk stage IB\u2011IIB cervical cancer undergoing radical hysterectomy followed by TP as adjuvant chemotherapy. Oncol Lett. 2023;26:353.","journal-title":"Oncol Lett"},{"key":"4149_CR4","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1200\/JCO.2000.18.8.1606","volume":"18","author":"WA Peters 3rd","year":"2000","unstructured":"Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr., Alberts DS. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncology: Official J Am Soc Clin Oncol. 2000;18:1606\u201313.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"4149_CR5","doi-asserted-by":"crossref","unstructured":"da Silva P, Molino GOG, Dias MMF, Pereira AGA, Pimenta NDS, Cavalcante DVS, de Farias Santos ACF, Ferreira SH, da Silva Santos R. A.A. Da Silva Reis, adjuvant radiotherapy for Intermediate-Risk Early-Stage cervical cancer post radical hysterectomy: A systematic review and Meta-Analysis. J Clin Med. 2025;14(11):4002.","DOI":"10.3390\/jcm14114002"},{"key":"4149_CR6","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S1470-2045(23)00147-X","volume":"24","author":"LR Mileshkin","year":"2023","unstructured":"Mileshkin LR, Moore KN, Barnes EH, Gebski V, Narayan K, King MT, et al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:468\u201382.","journal-title":"Lancet Oncol"},{"key":"4149_CR7","doi-asserted-by":"publisher","first-page":"5802","DOI":"10.1200\/JCO.2008.16.4368","volume":"26","author":"Reducing uncertainties about","year":"2008","unstructured":"Reducing uncertainties about. The effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncology: Official J Am Soc Clin Oncol. 2008;26:5802\u201312.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"4149_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12938-025-01390-9","volume":"24","author":"J Xu","year":"2025","unstructured":"Xu J, Ji Q, Deng J, Yu F. Concurrent vs. sequential chemoradiotherapy: a survival boost for lung cancer patients. Biomed Eng Online. 2025;24:60.","journal-title":"Biomed Eng Online"},{"key":"4149_CR9","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/jamaoncol.2025.2191","volume":"11","author":"F Xue","year":"2025","unstructured":"Xue F, Ou D, Xie C, Lin S, Li J, Chen X, et al. Sequential vs induction plus concurrent chemoradiotherapy in nasopharyngeal carcinoma: a randomized clinical trial. JAMA Oncol. 2025;11:1011\u201320.","journal-title":"JAMA Oncol"},{"key":"4149_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1001\/jamaoncol.2020.7168","volume":"7","author":"H Huang","year":"2021","unstructured":"Huang H, Feng YL, Wan T, Zhang YN, Cao XP, Huang YW, Xiong Y, Huang X, Zheng M, Li YF, Li JD, Chen GD, Li H, Chen YL, Ma LG, Yang HY, Li L, Yao SZ, Ye WJ, Tu H, Huang QD, Liang LZ, Liu FY, Liu Q, Liu JH. Effectiveness of sequential chemoradiation vs concurrent chemoradiation or radiation alone in adjuvant treatment after hysterectomy for cervical cancer: the STARS phase 3 randomized clinical trial. JAMA Oncol. 2021;7:361\u20139.","journal-title":"JAMA Oncol"},{"key":"4149_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/jjco\/hyac211","volume":"53","author":"M Saito","year":"2023","unstructured":"Saito M, Tanabe H, Yamauchi K, Kuroda T, Takano H, Yamada K, Okamoto A. Evaluation of non-hematologic toxicity in patients with cervical cancer after type 3 radical hysterectomy followed by concurrent chemoradiotherapy: a retrospective study. Jpn J Clin Oncol. 2023;53:393\u2013400.","journal-title":"Jpn J Clin Oncol"},{"key":"4149_CR12","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.2214\/AJR.19.21819","volume":"214","author":"M Saleh","year":"2020","unstructured":"Saleh M, Virarkar M, Javadi S, Elsherif SB, de Castro Faria S, Bhosale P. Cervical cancer: 2018 revised international federation of gynecology and obstetrics staging system and the role of Imaging, AJR. Am J Roentgenol. 2020;214:1182\u201395.","journal-title":"Am J Roentgenol"},{"key":"4149_CR13","first-page":"660","volume-title":"Cervical cancer, version 1.2020, journal of the National comprehensive cancer network","author":"NR Abu-Rustum","year":"2020","unstructured":"Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Huh WK, Lurain Iii JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Sisodia R, Tillmanns T, Ueda S, Urban R, Wyse E, McMillian NR, Motter AD. Cervical cancer, version 1.2020, journal of the National comprehensive cancer network. Volume 18. NCCN Guidelines Insights: JNCCN; 2020. pp. 660\u20136."},{"key":"4149_CR14","first-page":"649","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET. Carbone Toxic Response Criteria East Coop Oncol Group. 1982;5:649\u201356. P.J.A.j.o.c.o.","journal-title":"Carbone Toxic Response Criteria East Coop Oncol Group"},{"key":"4149_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176\u201381.","journal-title":"Semin Radiat Oncol"},{"key":"4149_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13014-023-02205-8","volume":"18","author":"BZ Zhang","year":"2023","unstructured":"Zhang BZ, Li Y, Xu LM, Chai YL, Qu C, Cao YJ, Wang J, Hou HL, Zhang J. The relationship between the radiation dose of pelvic-bone marrow and lymphocytic toxicity in concurrent chemoradiotherapy for cervical cancer. Radiation Oncol (London England). 2023;18:12.","journal-title":"Radiation Oncol (London England)"},{"key":"4149_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2174\/1874471015666221010141250","volume":"16","author":"X Ye","year":"2023","unstructured":"Ye X, Zhou J, Guo S, Lou P, Ma R, Guo J. The undervalued acute leukopenia induced by radiotherapy in cervical Cancer. Curr Radiopharm. 2023;16:50\u20136.","journal-title":"Curr Radiopharm."},{"key":"4149_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000533122","volume":"88","author":"YN Wang","year":"2023","unstructured":"Wang YN, Zhong ML, Liang MR, Yang JT, Zeng SY. The therapeutic value of adjuvant chemotherapy after concurrent chemoradiotherapy for locally advanced cervical cancer. Gynecol Obstet Invest. 2023;88:286\u201393.","journal-title":"Gynecol Obstet Invest"},{"key":"4149_CR19","doi-asserted-by":"publisher","first-page":"895","DOI":"10.7150\/jca.82801","volume":"14","author":"X Yang","year":"2023","unstructured":"Yang X, Li Z, Zhang L, Li H, Yang X, Sun Y, Liu L, Fu J. The effect of radiotherapy time and dose on acute hematologic toxicity during concurrent postoperative chemoradiotherapy for early high-risk cervical cancer. J Cancer. 2023;14:895\u2013902.","journal-title":"J Cancer"},{"key":"4149_CR20","doi-asserted-by":"publisher","first-page":"100649","DOI":"10.1016\/j.apjon.2024.100649","volume":"12","author":"X Lu","year":"2025","unstructured":"Lu X, Zheng L, Jin X, Wang Y, Wu S, Lv Y, Du H. Symptoms associated with concurrent chemoradiotherapy in patients with cervical cancer: application of latent profile analysis and network analysis. Asia-Pacific J Oncol Nurs. 2025;12:100649.","journal-title":"Asia-Pacific J Oncol Nurs"},{"key":"4149_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2371008","volume":"56","author":"YY Chen","year":"2024","unstructured":"Chen YY, Huang YT. Comparison of two platinum-containing chemotherapy regimens in the treatment of advanced cervical cancer with concurrent chemoradiotherapy. Ann Med. 2024;56:2371008.","journal-title":"Ann Med"},{"key":"4149_CR22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.acra.2022.08.002","volume":"30","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Liu L, Zhang K, Su R, Jia H, Qian L, et al. Nomograms combining clinical and imaging parameters to predict recurrence and disease-free survival after concurrent chemoradiotherapy in patients with locally advanced cervical cancer. Acad Radiol. 2023;30:499\u2013508.","journal-title":"Acad Radiol"},{"key":"4149_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1131803","volume":"13","author":"C Ming","year":"2023","unstructured":"Ming C, Bai X, Zhao L, Yu D, Wang X, Wu Y. RPL24 as a potential prognostic biomarker for cervical cancer treated by Cisplatin and concurrent chemoradiotherapy. Front Oncol. 2023;13:1131803.","journal-title":"Front Oncol"},{"key":"4149_CR24","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.12669\/pjms.39.4.6784","volume":"39","author":"G Jin","year":"2023","unstructured":"Jin G, Li K, Niu S, Fan X, Guo Y. Efficacy and safety of intensity modulated radiation therapy combined with concurrent chemoradiotherapy in the treatment of recurrent cervical cancer. Pak J Med Sci. 2023;39:1062\u20137.","journal-title":"Pak J Med Sci"},{"key":"4149_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1426002","volume":"14","author":"Y Gao","year":"2024","unstructured":"Gao Y, Wang H, Jiang M. Comparative effectiveness of neoadjuvant chemotherapy plus surgery versus concurrent chemoradiotherapy in stages IB2 to IIB of cervical cancer: a meta-analysis. Front Oncol. 2024;14:1426002.","journal-title":"Front Oncol"},{"key":"4149_CR26","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1089\/cbr.2023.0199","volume":"39","author":"L Hua","year":"2024","unstructured":"Hua L, Wei M, Feng C, Li S, Wen X, Chen S. Nomogram for predicting survival in locally advanced cervical cancer with concurrent chemoradiotherapy plus or not adjuvant chemotherapy: a retrospective analysis based on 2018 FIGO staging. Cancer biotherapy & radiopharmaceuticals. 2024;39:690\u2013705.","journal-title":"Cancer biotherapy & radiopharmaceuticals"},{"key":"4149_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1094081","volume":"10","author":"M Yang","year":"2023","unstructured":"Yang M, Pei B, Hu Q, Li X, Fang X, Huang X, et al. Effects of selenium supplementation on concurrent chemoradiotherapy in patients with cervical cancer: a randomized, double-blind, placebo-parallel controlled phase II clinical trial. Front Nutr. 2023;10:1094081.","journal-title":"Front Nutr"},{"key":"4149_CR28","doi-asserted-by":"publisher","first-page":"e22407","DOI":"10.1016\/j.heliyon.2023.e22407","volume":"9","author":"H Tie","year":"2023","unstructured":"Tie H, Shi L, Wang L, Hao X, Fang H, Li L. Symptom clusters and characteristics of cervical cancer patients receiving concurrent chemoradiotherapy: a cross-sectional study. Heliyon. 2023;9:e22407.","journal-title":"Heliyon"},{"key":"4149_CR29","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1186\/s12885-025-14196-8","volume":"25","author":"HY Yoon","year":"2025","unstructured":"Yoon HY, Kim JM, Jeong YY, Lee YH, Kim MJ, Choi YS, Ryu JM, Chong GO. Comparison of oncological outcomes and complication rate between radical hysterectomy and concurrent chemoradiotherapy in stage IIICr cervical cancer without parametrial invasion. BMC Cancer. 2025;25:811.","journal-title":"BMC Cancer"},{"key":"4149_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15113034","author":"CS Chen","year":"2023","unstructured":"Chen CS, Huang EY. Comparison of oncologic outcomes between radical hysterectomy and primary concurrent chemoradiotherapy in women with bulky IB and IIA cervical cancer under risk stratification. Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15113034.","journal-title":"Cancers"},{"key":"4149_CR31","doi-asserted-by":"publisher","first-page":"e0282710","DOI":"10.1371\/journal.pone.0282710","volume":"18","author":"A Takada","year":"2023","unstructured":"Takada A, Yokota H, Nemoto MW, Horikoshi T, Matsumoto K, Habu Y, et al. Prognosis prediction of uterine cervical cancer using changes in the histogram and texture features of apparent diffusion coefficient during definitive chemoradiotherapy. PLoS One. 2023;18:e0282710.","journal-title":"PLoS One"},{"key":"4149_CR32","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.62347\/PJVO5304","volume":"17","author":"J Liao","year":"2025","unstructured":"Liao J, Li J, Hu T, Nan Y. Endostar and chemoradiotherapy for advanced cervical cancer: comparing efficacy and prognosis. Am J Transl Res. 2025;17:1388\u2013401.","journal-title":"Am J Transl Res"},{"key":"4149_CR33","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40364-024-00655-0","volume":"12","author":"R Huang","year":"2024","unstructured":"Huang R, Wang F, Zou W, Li X, Lei T, Li P, Song Y, Liu C, Yue J. Tumor endothelium-derived PODXL correlates with immunosuppressive microenvironment and poor prognosis in cervical cancer patients receiving radiotherapy or chemoradiotherapy. Biomark Res. 2024;12:106.","journal-title":"Biomark Res"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04149-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04149-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04149-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:28:46Z","timestamp":1768994926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-025-04149-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4149"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04149-7","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has received formal approval from the Institutional Review Board (IRB) and Ethics Committee of Shanxi Provincial People\u2019s Hospital. Given that this study only uses de-identified patient data and poses no potential risks or adverse effects to participants, the IRB and Ethics Committee jointly decided to waive the requirement for informed consent in accordance with the relevant regulatory and ethical standards governing retrospective studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}